



Value Chains of Botanical and Herbal Medicinal Products: A 
European Perspective
Booker, A. and Heinrich, M.
 
This is a copy of the final version of an article published in HerbalGram, vol. 112, pp. 40-
45 in 2016.
It is reproduced here with permission and is available from the publisher at:
http://cms.herbalgram.org/herbalgram/index.html
The WestminsterResearch online digital archive at the University of Westminster aims to make the 
research output of the University available to a wider audience. Copyright and Moral Rights remain 
with the authors and/or copyright owners.
Whilst further distribution of specific materials from within this archive is forbidden, you may freely 
distribute the URL of WestminsterResearch: ((http://westminsterresearch.wmin.ac.uk/).
In case of abuse or copyright appearing without permission e-mail repository@westminster.ac.uk
40  •  I S S U E  112  •  2016  •  www.herbalgram.org
By Anthony Booker, PhD,1,2 and  
Michael Heinrich, Dr. rer. nat. habil.1
1 Research Cluster Biodiversity and Medicines/Centre for Pharmacognosy and Phytotherapy, University College London 
(UCL) School of Pharmacy, University of London
2 Division of Herbal and East Asian Medicine, Department of Life Sciences, University of Westminster, London
VALUE CHAINS OF BOTANICALS 
AND HERBAL MEDICINAL PRODUCTS: 
A European Perspective 
This overview discusses the concept of value chains 
(some have referred to them as “value networks”2), 
emphasizing that it offers a framework for assessing 
the current quality problems with botanical raw 
materials and extracts with respect to their adul-
teration, and for developing strategies for best 
practices in the global botanical industry. We 
propose that some form of self-regulation, if it 
enforces good quality and follows best practices, 
will need to be linked to an understanding of 
value chains by those selling final products, irre-
spective of their regulatory status. Importantly, 
the concept of value chains also involves an under-
standing of the socioeconomic impact of differ-
ent production systems on primary producers and 
other stakeholders.
The examples discussed here are based on 
studies of plant-based products sold in Europe 
(and, to a lesser degree, in North America) 
and compares regulated products with unreg-
ulated products, since such distinctions apply 
in Europe, per below.
The Need for Value Chains
An important difference between, for exam-
ple, the United States and member states of the 
European Union (EU) is the level of regulation of 
plant-based products and the subsequent enforce-
ment of the regulations. The European system 
offers an example of how quality assurance 
was introduced over the last 15 years. In the 
EU, traditional herbal registration (THR), 
as established by EU Directive 2004/24/
EC,3 has set minimum standards that aspire 
to guarantee the quality and safety of herbal 
medicinal products sold with medical claims 
for minor self-limiting diseases. The THR 
is one of several regulatory frameworks, and many 
European countries also regulate products under the 
Well-Established Use Directive4 (Article 10(a) of 
EU Directive 2001/83/EC, as amended) or under 
national regulations that allow for full licensing as 
medicines.
THR is an example that highlights how consist-
ent and high-quality herbal medicines can be 
produced by using such a regulatory framework. 
Alternatively, a company could go for a more 
rigorous and well-enforced self-regulation, driven 
by the relevant industry bodies. The introduction 
of more rigorous standards implemented at a global 
level results in a greater integration between some 
processors and primary producers, who are then 
able to ascertain better quality and to obtain more 
stable prices. Such standards could be based on a 
regulatory framework or on commonly agreed-
upon principles of best practice, which are certi-
fied, for example, by an external agency. 
A useful framework to achieve this improved 
quality is the concept of value chains, which for 
certain key food products (e.g., coffee [Coffea 
arabica, Rubiaceae], tea [Camellia sinensis, 
Theaceae], and cocoa [Theobroma cacao, Malva-
ceae]) have been investigated widely. However, 
value chains of medicinal botanicals have been 
largely ignored in the global research literature.5,6 
Analysis of the value chains of botanicals is impor-
tant, since it is a critical part of understanding the 
quality and safety breakdowns that can occur 
Introduction
In recent years, the quality of botanicals has come under increased scrutiny. Despite the availability of numer-
ous high-quality products from reputable companies, health care professionals, patients, and consumers are under-
standably concerned about questionable botanical ingredients in various consumer products. In Europe, this 
includes products that are generally unlicensed and unregistered supplements (also referred to as “botanicals”), 
which are often poorly regulated, or even totally unregulated, depending on the country of jurisdiction.*
*The American Botanical Council (ABC) has been 
actively bringing together stakeholders inter-
ested in educational efforts intended to help 
reduce the level of adulteration and contamina-
tion of ingredients used in such products.1
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along the chain — breakdowns that are likely to result in 
sub-standard or even unsafe finished products for consum-
ers. While this is in no way a new problem (in fact, phar-
macognosy as a scientific discipline has resulted, at least 
partially, from the need to identify adulteration and define 
best quality), it has become an evermore relevant problem 
with the rapid and dramatic globalization of trade in botan-
icals and herbal medicinal products.
A value chain differs conceptually from a supply or 
commodity chain in that it is founded upon the insight that 
any company is more than a random assembly of machin-
ery, people, and finance. Only if these things are arranged 
into definable systems will it become possible to produce a 
higher quality commodity for which customers are willing 
to pay.7
In our own research on botanicals and regulated phyto-
medicines, we have found that value addition can be intro-
duced at various stages of production. This can occur, for 
example, through certified organic cultivation, use of supe-
rior extraction techniques, and/or through more stringent 
regulation, such as the European THR.8-10
For example, in the case of saw palmetto (Serenoa repens, 
Arecaceae) berry we found that regulated products manu-
factured using an extraction process with a soft gelatin 
capsule dosage form were typically of higher quality and 
more consistent than other products tested.11 In the case of 
Rhodiola rosea (Crassulaceae) root products, we found that 
approximately one quarter of products that were marketed 
without a THR were of poorer phytochemical quality 
than those marketed with a THR as Traditional Herbal 
Medicines (THMs).10 In addition, some of these products 
were adulterated with other species or did not meet their 
label specifications. This does not mean that all non-THR 
products were of poor quality. In fact, some sold as botan-
icals were comparable. One major problem with non-THR 
products is that it is practically impossible for consumers 
to differentiate high-quality products from low-quality 
products. Our data confirm that by choosing a THR prod-
uct, the quality and safety are 
assured.
Benefits of Vertical 
Integration
We suggest that vertical inte-
gration, in which contracts are 
made directly with the farmers 
and primary processors, not 
only benefits those involved in 
primary production but also 
can lead to higher quality prod-
ucts for consumption in more 
economically developed coun-
tries. In such a value chain, a 
lead organization is responsible 
for two or more intertwined 
steps of the manufacturing or 
value chain process. Vertical 
integration, however, has been 
criticized as resulting in a high 
degree of dependence on the primary producers.9
The product quality and economic benefits for a primary 
producer are highlighted in our work on turmeric (Curcuma 
longa, Zingiberaceae).12 Looking at the production process 
of a multipurpose product containing turmeric root and 
rhizome, we found that turmeric derived from organi-
cally grown crops in India under contract from a Euro-
pean manufacturer retained more volatile phytochemi-
cal compounds. Such compounds are generally lost when 
turmeric is stored for long periods (e.g., when the market 
price is low). Moreover, we found that some products that 
were obtained through middlemen were the wrong species 
and thus did not meet the label claims (Figure 1).
Products derived from a vertically integrated value chain 
(VIVC) have obvious benefits for the consumer and, based 
on our assessment, the producers as well. The producers we 
evaluated in India, who were able to access the international 
market and agree to a quantity and price with the manufac-
turer prior to cultivation, were less susceptible to the price 
fluctuations and market shocks that can easily upset the 
smooth and expedient transfer of goods from one country 
to another.12
Value chains of botanicals and herbal medicinal products 
can be highly diverse. Vertical integration is not widespread 
throughout the industry, and free markets and middle-
men are still the most common routes of supply. Supply 
chains for cultivated materials and wild-collected materials 
each have associated challenges, and the picture is further 
complicated by a lack of regulatory harmonization among 
different global regions and countries, including many that 
are within the EU.
In our own investigations,10-12 we found that a VIVC 
was conducive to the manufacture of organically grown 
products in which it is a requirement that traceability to 
the exact area of origin can be proved, and documented 
procedures for any primary processing are implemented 
(Figure 2).
More phytochemicals were present in the fresh rhizome samples 38, 39, and 40. The inte-
grated chain powder samples 47, 12, and 13 displayed a strong zone at Rf 0.25, which was 
also observed for the fresh rhizome samples. The integrated chain samples and the fresh 
rhizome samples also displayed a stronger zone at Rf 0.83. Sample 19 displayed a different 
pattern, and the bisdemethoxycurcumin zone at Rf 0.2 was missing, which indicates that 
this sample was not Curcuma longa. 
Figure 1. HPTLC Chromatogram of Various Turmeric Root/Rhizome 
Samples and Powdered Products
THR vs. Non-THR Products
Multiple factors differentiate products produced with a THR. 
Although there is no requirement for a THR product to be linked to 
any particular value chain, a company’s commitment to and consid-
erable financial investment in obtaining a THR constitutes a signifi-
cant value addition to the product (Table 1), and it requires the estab-
lishment of robust systems of quality control, from good agricultural 
and collection practices (GACPS) to good manufacturing practices 
(GMPs) throughout the value chain.
THR products used to treat minor self-limiting 
conditions are now widely available within the EU. 
It is a legal requirement for any product that makes 
a medicinal claim, or any product that is deemed to 
have a significant pharmacological effect, to hold a 
registration before being placed on the market.13 Such products can 
be readily identified by their unique THR number, and many also 
display the THR logo.
Food supplements (botanicals), however, are not yet required to 
have a THR before entering the market in Europe, and they remain 
widely unmonitored. Although regulations do exist, they are rarely 
cited or enforced. Food supplements are often mislabeled or make 
misleading claims, and the lack of effective enforcement in Europe 
has resulted in a large number of these products entering the market.
The value chains of food supplements typically are undisclosed, 
and it is only through careful analysis of the products that prob-
lems may be detected. In our unpublished investigation of milk 
thistle (Silybum marianum, Asteraceae) fruit extract and our analy-
sis of ginkgo (Ginkgo biloba, Ginkgoaceae) leaf extract products,14 
carried out in collaboration with the BBC for its series Trust Me, I’m 
a Doctor,15 we found widespread quality and adulteration problems. 
Approximately 40% of unregistered milk thistle products, sold legally 
as supplements in the EU, contained very low levels of the bioactive 
marker compounds collectively referred to as silymarin. Furthermore, 
after a detailed investigation, we found that more than 50% of ginkgo 
products either were not compliant with their label claims; contained 
high levels of flavonols, rutin, and/or quercetin; or were adulterated, 
one with a 5-hydroxytryptophan (5-HTP) derivative.
Wild-collected vs. Cultivated Material
The impact that different value chains have on botanicals and 
herbal medicinal products and their quality also can be linked to live-
lihoods and sustainability. Many rural communities and indigenous 
groups, particularly in Asia, depend 
on medicinal plant collection for their 
livelihoods.16 A common pattern can 
be seen across different countries: As 
collected plants are depleted in the 
wild, their scarcity in the marketplace 
increases along with their economic 
value. This drives collectors to travel 
to isolated and potentially dangerous 
areas in order to find more of the raw 
material, or to use superficially simi-
lar material that can be sourced at 
lower cost. The collectors themselves, 
however, are often unaware of the 
true market value of the plants they 
collect and are prone to exploitation by 
middlemen. 
Figure 2. Cultivation and 
Primary Processing of 
Phytomedicines in an 
Integrated Chain
Photo A: Medicinal plants 
are harvested and put 
through a tiered wash cycle.
Photo B: After washing, the 
crops are dried in a covered 
area on designated racks.
Photo C: The dried material 
is cut into the required size 
at the factory.
Photo D: The dried material 
is then checked for foreign 
matter.





42  •  I S S U E  112  •  2016  •  www.herbalgram.org
www.herbalgram.org  •  2016  •  I S S U E  112  •  43
The pressure to find more material may lead to adulter-
ation of the crop with similar species (e.g., as with Rhodi-
ola species) or adulteration further down the value chain. 
Another example is the adulteration of ginkgo products 
with lower-cost rutin derived from buckwheat (Fagopyrum 
esculentum, Polygonaceae). This is done in order to increase 
the flavonoid content of the product and to achieve a super-
ficial similarity to some of the existing analytical standards 
that relate to ginkgo leaf extract. Clearly all such products, 
if they do not comply with the label claim, are put on the 
market illegally. 
An integrated chain using cultivated material may provide 
a better alternative to these models, but a major drawback 
for many manufacturers and retailers is the cost. Cultivated 
material is typically more expensive than wild-collected 
material, especially when it is produced in more economi-
cally developed countries. This is particularly true for root 
crops that require a number of years of growth before they 
can be harvested, such as Asian ginseng (Panax ginseng, 
Araliaceae) and rhodiola. These crops are typically grown 
for four to six years before harvesting and incur consider-
able expenditure of both time and money. There are also 
concerns by some that cultivated material may be in some 
way inferior to wild-collected material, and that certain 
cultivated plant-based products may be less appealing to 
consumers.
Welfare Effects
Some companies, including manufacturers of food 
supplements containing botanical ingredients, have 
managed not only to find a way to cultivate their own 
crops, but also to use the VIVC model to their advan-
tage. In doing so, they highlight to the general public the 
high quality of their products due to the tight controls 
employed along the chain, and raise awareness of the 
potential welfare effects that such chains can have on 
the primary producers in 
less economically devel-
oped countries (e.g., in 
India and Eastern Euro-
pean countries).17 These 
welfare effects may not be 
sizeable in terms of hard 
cash but can help in some 
practical ways, and will 
be of longer-term bene-
fit. For example, farmers can plan their crops based on 
definite orders, which can give farm workers and those 
involved in primary processing fixed terms of employ-
ment, rather than having to travel the country in search 
of farm labor or factory-based employment.
The VIVC model has some obvious similarities to the 
Fairtrade approach.* However, in order to gain Fairtrade 
certification, farmers need to have a certain amount of infra-
structure already in place. Consequently, it is not always a 
suitable partnership for the poorest farmers.18 The partner-
ships that have been built between farmers and companies 
Rhodiola crenulata is collected 
at high altitude on the Chinese 
Sichuan-Tibet border. Rhodiola 
crenulata is used in the Chinese 
medicine industry, but based on 
the European Pharmacopoeia, 
for example, it is an adulterant. 
In other cases (if no specific 
label claims are made) it could 
be considered a substitute.
Photo ©2016 Anthony Booker
Table 1. Comparing Benefits and Risks: THR Products vs. Non-THR Products
THR Products Non-THR Products
Benefits Risks
Cultivation & Collection Practices
Quality from the source — Controlled agricultural, cultivation, and 
collection practices.
Reliance on middlemen — Limited botanical knowledge may lead 
to misidentification of plant material.
Primary Processing
According to good manufacturing practices — Batch integrity is 
maintained throughout processing. In-house quality control.
Variable standards followed — Poor controls, including container, 
packaging, and storage, can lead to spoilage. 
Manufacturing
Standard operating procedures — Tightly controlled processing leads 
to consistently high-quality products.
Manufacture may be poorly controlled — Lack of standard proce-
dures can result in lower quality finished products.
Retail
Defined shelf-life based on extensive stability studies — High 
confidence in product integrity during specified shelf-life.
Often lacking meaningful stability studies —Prolonged shelf-life 
can lead to deterioration of product due to spoilage.
Consumers
Purchases registered product — Consumer has confidence that the 
product is safe and of good quality.
Purchases unregistered product — Variable quality and safety. 
Consumers are poorly informed about products.
* Fairtrade (www.fairtrade.net) was established to support farmers and farm workers, mainly in less economically developed countries. The 
Fairtrade mark gives consumers the knowledge that workers have been paid a fair price and work under a set of agreed-upon working condi-
tions.
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producing both regulated and unregulated end products may 
offer an extra level of support for some of these poorest work-
ers. Of course, a more informal fair-trade VIVC approach can 
also have its dangers without good governance. Some studies 
suggest that certain VIVCs, particularly ones that are domi-
nated by a single powerful company, can lead to negative 
effects on the livelihoods of small producers.19 Only through 
the establishment of mutual trust over a period of time (quasi-
vertical integration) can these partnerships be successful and 
flourish. 
A comparison of the different value chain approaches along 
with their main risks and benefits is given in Table 2. In 
comparing both tables, it becomes apparent that VIVCs and 
THR-driven supply systems have a number of similarities, 
most importantly as they relate to the possibility of ascertain-
ing a consistent, high-quality end product. 
Conclusion
Overall, to both producers and consumers, VIVCs appear 
to offer some distinct advantages over the reliance on middle-
men that often occurs in a free-market system. However, in a 
market in which cost may still be the major driving force for 
most consumers of botanicals and herbal medicinal products, 
it is unlikely that VIVCs will become commonplace without 
sufficient consumer-driven demand for a specific group of 
products (e.g., demand for organically grown raw materials). 
The examples presented here offer models for how to ascer-
tain the best quality botanicals and herbal medicinal products. 
The research highlights not only the need for taking a broader 
approach with regard to quality control (including an under-
standing of best practices from source to consumer), but also 
that either regulation or self-regulation of the relevant industry 
is essential for quality assurance.
The lack of any government strategies for the effective 
cultivation, process-management, and regulation of wild-
sourced medicinal or locally grown (often by smallholders) 
plant material — particularly plant material originating from 
less economically developed countries — is a major cause 
for concern for producers, manufacturers, and consumers 
of plant-based products. However, VIVC-based approaches, 
which encompass effective partnerships, ethical trading, and 
good governance, can help provide a more stable platform 
from which safe and high-quality products can be sustainably 
produced. 
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Table 2. Comparing Benefits and Risks: Vertically Integrated Value Chains vs. Free-Market Approach
Vertically Integrated Value Chains Free-Market Approach
Benefits Risks
Cultivation & Collection Practices
Controlled agricultural, cultivation, and collection practices through 
on-site training and detailed customer requirements (e.g., organically 
grown).
Impossible to control or influence collection and cultivation practices. 
Reliable traceability of defined batches often is lost along the chain.
Primary Processing
Company is in a stronger position to request and agree to primary 
processing procedures with the producers.
How the harvested crop is initially processed (e.g., cutting and drying) is 
largely unknown.
Producers
Producer benefits from agreeing to known quantities of crops at fixed 
prices. Staff can benefit from training and input.
Producer may reap greater financial benefits when prices are high but 
can experience big losses when market prices crash.
Buyers (Retailers)
Buyer is able to have some control along the length of the chain and 
plan for following years.
Buyer maintains control of product only after it has been purchased. 
Buyer can be affected by price fluctuations and shortages.
Consumers
Good traceability back to the fields or collection areas. May be better 
quality.
Often little or no traceability. May be lower-cost, but quality may be 
poorer.
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Key Findings from UCL Investigations of Botani-
cals and Herbal Medicinal Products 
In 2010, the research group of Michael Heinrich, Dr. rer. nat. 
habil, at the UCL School of Pharmacy in London initiated a 
series of investigations of the authenticity and identity of vari-
ous herbal medicinal products and herbal food supplements 
sold in the United Kingdom and links to different value chains 
of such products. 
In our initial project, we investigated value chains of turmeric, 
which is grown as a cash crop throughout India.12 It is generally 
sold at auction, and the price can be variable from one year to 
the next. When the price is high one year, it encourages farm-
ers to plant more, frequently resulting in an excess of crop the 
following year, which usually leads to a fall in the price. This is 
pure supply-demand economic dynamics. When the price is 
low, farmers may store the dried crop rather than sell it. The 
dried turmeric rhizomes can sometimes be stored for years in 
poor conditions, and farmers can rely on heavy use of pesti-
cides and other chemicals to keep the material from degrading 
or perishing. Our analytical data suggested that this long-term 
storage also can result in the loss of therapeutically important, 
mainly volatile compounds (e.g., tumerone) that can evaporate 
over time. 
We also investigated rhodiola products (i.e., herbal prod-
ucts made from roots of plants in the genus Rhodiola). These 
included both registered herbal products and unregistered 
food supplements used for the prevention or treatment of 
fatigue and widely used to improve sports performance. We 
looked at 39 products available in health food stores and on the 
internet and found that approximately 25% of these products 
were of poor quality.10 The main problem was that an incorrect 
species had been used. Instead of the preferred R. rosea — the 
species of Rhodiola that has the most clinical research — the 
lower-cost Chinese species R. crenulata had been substituted 
in its place, even though 34 products claimed on the label to 
contain only R. rosea. Although R. crenulata is used medicinally 
in China, it does not contain the important compounds that 
give R. rosea its reputation as an effective adaptogenic medic-
inal product. More troublesome, a selection of the samples 
appeared to contain no Rhodiola species, and one was found 
to contain 5-HTP, a naturally occurring compound with reputed 
antidepressant properties. All of the THR products (n = 10) 
complied with their label specifications.
With ginkgo and milk thistle, we used a similar sampling 
strategy to rhodiola, using the internet, visiting high street 
supermarkets, pharmacies, and health food shops, and obtain-
ing a reasonably representative sample of products available to 
UK consumers (ginkgo: n = 35; milk thistle: n = 18). Once again 
we found that 22% of all milk thistle products and 25% of all 
ginkgo products were of very poor quality when compared to 
the reference material or to THR products.14 The quality prob-
lems included low concentrations of key compounds (with 
some being almost undetectable) when compared to reference 
products commonly used in intervention and clinical studies, 
and adulteration with other substances. Since the original work 
was done, we have looked more closely at the ginkgo samples 
and suggest that more than 50% contain low levels of ginkgo, 
and thus also are poor quality products. Some ginkgo samples 
appeared to have greater quantities of rutin than were detect-
able in the reference material. This suggests that they had 
been “spiked” — a process in which exogenous rutin is added 
to increase the total flavonoid content, making it appear that 
the samples are of acceptable quality. And again we found that 
one product contained a 5-HTP-related compound. This prod-
uct was from the same company as the adulterated rhodiola 
product.
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